Ocular Adverse Events for Five SNRIs from FAERS, 2004-2024

A retrospective pharmacovigilance analysis of 5,860 ocular adverse event reports associated with five SNRIs extracted from the FDA Adverse Event Reporting System (FAERS) database from Q1 2004 to Q4 2024. The study, authored by Zhengtai Sun, used disproportionality analyses to identify drug-specific and sex-specific safety signals.

Use Cases

• Compare ocular safety signals between SNRIs like venlafaxine and duloxetine based on disproportionality analysis results.
• Analyze time-to-onset patterns for adverse events across different drugs based on the reported median days.
• Investigate sex-specific differences in reported ocular adverse events based on subgroup analyses mentioned.
• Identify the most frequently reported ocular adverse events (e.g., vision blurred, visual impairment) across all studied drugs.

Strengths

• Covers a 20-year time range (2004-2024) of real-world adverse event data from the FAERS database.
• Analyzes 5,860 specific adverse event reports, providing a substantial case count.
• Employs four established disproportionality analysis algorithms (PRR, ROR, BCPNN, MGPS) for signal detection.

Limitations

• Row count for the underlying dataset is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is small (64.6 KB), indicating limited scope or highly summarized data.

Provenance

Source

FDA Adverse Event Reporting System (FAERS)

Collection Method

Retrospective pharmacovigilance analysis with disproportionality and time-to-onset calculations.

Time Range

Q1 2004 to Q4 2024

Freshness

Last updated 2026-05-29 06:11:33; freshness should be verified.